# Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome

> **NCT05079529** · PHASE2 · UNKNOWN · sponsor: **University of Brawijaya** · enrollment: 70 (estimated)

## Conditions studied

- Cardiometabolic Syndrome

## Interventions

- **DRUG:** β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group
- **DRUG:** Placebo Group

## Key facts

- **NCT ID:** NCT05079529
- **Lead sponsor:** University of Brawijaya
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-30
- **Primary completion:** 2021-12-28
- **Final completion:** 2022-01-06
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2021-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05079529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05079529, "Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05079529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*